By collecting medical records from published case reports and case series involving IL-17 inhibitor-associated IBD, we revealed that diarrhea, bloody diarrhea, abdominal pain, and fever were the most common symptoms, which were often accompanied by elevated WBC count, ESR, C-reactive protein, and fecal calprotectin level. Here, IL17A is linked to inflammatory bowel disease.